From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Last Updated: Friday, May 19, 2023

This review article discusses safety of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, all of which are approved CD19-directed CAR T-cell therapies for patients with relapsed/refractory large B-cell lymphoma. Common adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are discussed, as are hemophagocytic lymphohistiocytosis and other events.

Expert Opinion on Drug Safety
Advertisement
News & Literature Highlights
Advertisement
Advertisement